Topic: mesothelioma

Novocure named Pritesh Shah chief commercial officer, to lead the tumor-treating device manufacturer’s international business units.

Novocure wants to bring the electric field device to market in mesothelioma via the rarely used humanitarian device exemption.

The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.

The deal gives Sellas a route to public investors as it seeks to guide its WT1-targeting drug through phase 3 trials in AML and mesothelioma.

The drug failed to improve progression-free survival in mesothelioma, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip.

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor cell therapy.

Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy.

The struggling biotech Verastem that has seen its stock nose-dive will look to a future without executive chairman Christoph Westphal and director Henri Termeer.

After a slew of failures in mesothelioma, there has been a small bright spot today after the FDA accepted an IND for Epizyme’s experimental treatment for the hard-to-treat cancer.